JP2020505395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505395A5 JP2020505395A5 JP2019540035A JP2019540035A JP2020505395A5 JP 2020505395 A5 JP2020505395 A5 JP 2020505395A5 JP 2019540035 A JP2019540035 A JP 2019540035A JP 2019540035 A JP2019540035 A JP 2019540035A JP 2020505395 A5 JP2020505395 A5 JP 2020505395A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- prodrug
- pharmaceutically acceptable
- acceptable salt
- stereoisomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 67
- 239000000651 prodrug Substances 0.000 claims description 34
- 229940002612 prodrug Drugs 0.000 claims description 34
- 150000003839 salts Chemical class 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 21
- 102200124918 rs121913250 Human genes 0.000 claims description 20
- 125000000217 alkyl group Chemical group 0.000 claims description 18
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims description 17
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 102100029974 GTPase HRas Human genes 0.000 claims description 14
- 102100030708 GTPase KRas Human genes 0.000 claims description 14
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims description 14
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 125000003118 aryl group Chemical group 0.000 claims description 14
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 14
- 125000004966 cyanoalkyl group Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 11
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 10
- 125000002837 carbocyclic group Chemical group 0.000 claims description 10
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 10
- -1 heterocyclylene Chemical group 0.000 claims description 10
- 230000035772 mutation Effects 0.000 claims description 10
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 8
- 102200006538 rs121913530 Human genes 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 6
- 102200006614 rs104894229 Human genes 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 102000008300 Mutant Proteins Human genes 0.000 claims description 4
- 108010021466 Mutant Proteins Proteins 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 208000015768 polyposis Diseases 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 206010027476 Metastases Diseases 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 2
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 2
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 claims description 2
- 239000012964 benzotriazole Substances 0.000 claims description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000004474 heteroalkylene group Chemical group 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 230000000155 isotopic effect Effects 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 229910017464 nitrogen compound Inorganic materials 0.000 claims 1
- 150000002830 nitrogen compounds Chemical class 0.000 claims 1
- 0 **(C(C1(*)*=C)c(cc2)cc(CCN3I*)c2C3=O)C(*=C)(*#C)N1I**C(*)=C* Chemical compound **(C(C1(*)*=C)c(cc2)cc(CCN3I*)c2C3=O)C(*=C)(*#C)N1I**C(*)=C* 0.000 description 96
- 125000001188 haloalkyl group Chemical group 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 5
- BDYKZMNDOYRQTR-UHFFFAOYSA-N CC(C)(C)c(c(F)ccc1)c1O Chemical compound CC(C)(C)c(c(F)ccc1)c1O BDYKZMNDOYRQTR-UHFFFAOYSA-N 0.000 description 3
- BQBGTRIOPZRLJD-UHFFFAOYSA-N CC(C)(C)c1cc(O)cc2c1cccc2 Chemical compound CC(C)(C)c1cc(O)cc2c1cccc2 BQBGTRIOPZRLJD-UHFFFAOYSA-N 0.000 description 3
- YCOXTKKNXUZSKD-UHFFFAOYSA-N Cc(c(C)c1)ccc1O Chemical compound Cc(c(C)c1)ccc1O YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 3
- CLVGCNBUFPYHNL-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2[IH]C Chemical compound Cc(ccc1c2cn[nH]1)c2[IH]C CLVGCNBUFPYHNL-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- SZYKUVMGNRTEQO-ALCCZGGFSA-N C/C(/C=C)=N/C#N Chemical compound C/C(/C=C)=N/C#N SZYKUVMGNRTEQO-ALCCZGGFSA-N 0.000 description 2
- PNYOCIAHBRDHNI-UHFFFAOYSA-N C=CC(N(C1)CC1C(C=CC1=CN2c3c(cccc4)c4cc(O)c3)=CC1=CC2=O)=O Chemical compound C=CC(N(C1)CC1C(C=CC1=CN2c3c(cccc4)c4cc(O)c3)=CC1=CC2=O)=O PNYOCIAHBRDHNI-UHFFFAOYSA-N 0.000 description 2
- UMUFTTSZQRBNMC-WUKNDPDISA-N C=CC(N(C1)CC1Nc1cccc2c1nccc2-c1cc(O)c(/C=C/C(N(C2)CC2NC(c(cc2)cc3c2c(-c2cc(O)cc4ccccc24)ccn3)=O)=O)c2c1cccc2)=O Chemical compound C=CC(N(C1)CC1Nc1cccc2c1nccc2-c1cc(O)c(/C=C/C(N(C2)CC2NC(c(cc2)cc3c2c(-c2cc(O)cc4ccccc24)ccn3)=O)=O)c2c1cccc2)=O UMUFTTSZQRBNMC-WUKNDPDISA-N 0.000 description 2
- AVPDXSMDPUAIBW-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc(CCN2c(c(F)ccc3)c3O)c1C2=O)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc(CCN2c(c(F)ccc3)c3O)c1C2=O)=O AVPDXSMDPUAIBW-UHFFFAOYSA-N 0.000 description 2
- SPWZDEAYVYSLPX-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc(CCN2c3cc(O)cc4c3cccc4)c1C2=O)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc(CCN2c3cc(O)cc4c3cccc4)c1C2=O)=O SPWZDEAYVYSLPX-UHFFFAOYSA-N 0.000 description 2
- ZMRXVNFPUMXBRI-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc(CN2c3cc(O)cc4ccccc34)c1C2=O)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc(CN2c3cc(O)cc4ccccc34)c1C2=O)=O ZMRXVNFPUMXBRI-UHFFFAOYSA-N 0.000 description 2
- JKHMBQUTNUJFMW-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc(N=CN2c3c(cccc4)c4cc(O)c3)c1C2=O)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc(N=CN2c3c(cccc4)c4cc(O)c3)c1C2=O)=O JKHMBQUTNUJFMW-UHFFFAOYSA-N 0.000 description 2
- DLJSHGJHCYCVKA-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc2c1[nH]c(-c1cc(O)cc3ccccc13)n2)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc2c1[nH]c(-c1cc(O)cc3ccccc13)n2)=O DLJSHGJHCYCVKA-UHFFFAOYSA-N 0.000 description 2
- YFSJDTTYYIYMIS-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(C(N(C2)c3c(cccc4)c4cc(O)c3)=O)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(C(N(C2)c3c(cccc4)c4cc(O)c3)=O)c2cc1)=O YFSJDTTYYIYMIS-UHFFFAOYSA-N 0.000 description 2
- XVVSMYJHZVVSFD-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(CCN(C2)c3cc(O)cc4ccccc34)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(CCN(C2)c3cc(O)cc4ccccc34)c2cc1)=O XVVSMYJHZVVSFD-UHFFFAOYSA-N 0.000 description 2
- KIBFIBJCKOHBRZ-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(CN(C2)c3cc(O)cc4ccccc34)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(CN(C2)c3cc(O)cc4ccccc34)c2cc1)=O KIBFIBJCKOHBRZ-UHFFFAOYSA-N 0.000 description 2
- NNSSDIFHBONUCU-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(NC(N(C2)c3c(cccc4)c4cc(O)c3)=O)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(NC(N(C2)c3c(cccc4)c4cc(O)c3)=O)c2cc1)=O NNSSDIFHBONUCU-UHFFFAOYSA-N 0.000 description 2
- DKWCBALJEQGPAH-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc([nH]c(-c2cc(O)cc3c2cccc3)c2)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc([nH]c(-c2cc(O)cc3c2cccc3)c2)c2cc1)=O DKWCBALJEQGPAH-UHFFFAOYSA-N 0.000 description 2
- VDSRHTWDCLODKP-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc([n](CC(N)=O)c(-c2cc(O)cc3c2cccc3)c2)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc([n](CC(N)=O)c(-c2cc(O)cc3c2cccc3)c2)c2cc1)=O VDSRHTWDCLODKP-UHFFFAOYSA-N 0.000 description 2
- YKWRZFRNLCJIGB-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc2cnc(-c3cc(O)cc4ccccc34)nc2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc2cnc(-c3cc(O)cc4ccccc34)nc2cc1)=O YKWRZFRNLCJIGB-UHFFFAOYSA-N 0.000 description 2
- XLCQCNZTMPLRKY-UHFFFAOYSA-N C=CC(N(C1)CC1c1ccc(cc(-c2c(cccc3)c3cc(O)c2)nc2)c2c1)=O Chemical compound C=CC(N(C1)CC1c1ccc(cc(-c2c(cccc3)c3cc(O)c2)nc2)c2c1)=O XLCQCNZTMPLRKY-UHFFFAOYSA-N 0.000 description 2
- TXMKSWYODQPDOX-UHFFFAOYSA-N C=CC(N(C1)CC1c1ccc2[nH]c(-c3cc(O)cc4ccccc34)cc2c1)=O Chemical compound C=CC(N(C1)CC1c1ccc2[nH]c(-c3cc(O)cc4ccccc34)cc2c1)=O TXMKSWYODQPDOX-UHFFFAOYSA-N 0.000 description 2
- FOPLPTAJAYOKDJ-UHFFFAOYSA-N C=CC(N(C1)CC1c1ccc2[n](CC(N)=O)c(-c3c(cccc4)c4cc(O)c3)cc2c1)=O Chemical compound C=CC(N(C1)CC1c1ccc2[n](CC(N)=O)c(-c3c(cccc4)c4cc(O)c3)cc2c1)=O FOPLPTAJAYOKDJ-UHFFFAOYSA-N 0.000 description 2
- TVQPLBTTZOWVGX-UHFFFAOYSA-N C=CC(N(CCO)I)=O Chemical compound C=CC(N(CCO)I)=O TVQPLBTTZOWVGX-UHFFFAOYSA-N 0.000 description 2
- BOPWEAOQGLABTB-FPYGCLRLSA-N CC(/C(/C#N)=C/c1nc(C)c[o]1)=O Chemical compound CC(/C(/C#N)=C/c1nc(C)c[o]1)=O BOPWEAOQGLABTB-FPYGCLRLSA-N 0.000 description 2
- UERNAGFZPQWNRM-AATRIKPKSA-N CC(/C=C/c(c(F)ccc1)c1O)=O Chemical compound CC(/C=C/c(c(F)ccc1)c1O)=O UERNAGFZPQWNRM-AATRIKPKSA-N 0.000 description 2
- NNKSQQOADOOAKK-IHWYPQMZSA-N CC(/C=C\C#N)=O Chemical compound CC(/C=C\C#N)=O NNKSQQOADOOAKK-IHWYPQMZSA-N 0.000 description 2
- MOGWTTHYHNMLNR-UHFFFAOYSA-N CC(C)(C)c1c(c(C)n[nH]2)c2ccc1C Chemical compound CC(C)(C)c1c(c(C)n[nH]2)c2ccc1C MOGWTTHYHNMLNR-UHFFFAOYSA-N 0.000 description 2
- RNWURRFCFKVJRF-XBXARRHUSA-N CC(C)(CO)/C=C(/C(C)=O)\C#N Chemical compound CC(C)(CO)/C=C(/C(C)=O)\C#N RNWURRFCFKVJRF-XBXARRHUSA-N 0.000 description 2
- ZDEZCDQCTBURCD-XBXARRHUSA-N CC(C)/C=C(/C(C)=O)\C#N Chemical compound CC(C)/C=C(/C(C)=O)\C#N ZDEZCDQCTBURCD-XBXARRHUSA-N 0.000 description 2
- XKFPNHDGLSYZRC-UHFFFAOYSA-N CC(CCC1)CN1C(C)=O Chemical compound CC(CCC1)CN1C(C)=O XKFPNHDGLSYZRC-UHFFFAOYSA-N 0.000 description 2
- NQNBFNQAKIMCKJ-UHFFFAOYSA-N CN(C(c1ccccc1)=Nc1c2cc(C(C3)CN3C(C=C)=O)cc1)C2=O Chemical compound CN(C(c1ccccc1)=Nc1c2cc(C(C3)CN3C(C=C)=O)cc1)C2=O NQNBFNQAKIMCKJ-UHFFFAOYSA-N 0.000 description 2
- QBMJWJJDVZNBTE-UHFFFAOYSA-N CN(c(cccc1)c1N1)S1(=O)=O Chemical compound CN(c(cccc1)c1N1)S1(=O)=O QBMJWJJDVZNBTE-UHFFFAOYSA-N 0.000 description 2
- GYFLGMBTHMVLEG-UHFFFAOYSA-N C[IH]c1cc(O)cc2c1cccc2 Chemical compound C[IH]c1cc(O)cc2c1cccc2 GYFLGMBTHMVLEG-UHFFFAOYSA-N 0.000 description 2
- JJXCQYVCILLXFK-UHFFFAOYSA-N Cc(c(C)c12)ccc1[nH]nc2C#N Chemical compound Cc(c(C)c12)ccc1[nH]nc2C#N JJXCQYVCILLXFK-UHFFFAOYSA-N 0.000 description 2
- OMGVVVBQKWNRQA-UHFFFAOYSA-N Cc(c(O)ccc1)c1F Chemical compound Cc(c(O)ccc1)c1F OMGVVVBQKWNRQA-UHFFFAOYSA-N 0.000 description 2
- JCLJFOALEJVDAC-UHFFFAOYSA-N Cc(cc1)c(C)c2c1[nH]nc2 Chemical compound Cc(cc1)c(C)c2c1[nH]nc2 JCLJFOALEJVDAC-UHFFFAOYSA-N 0.000 description 2
- HOXCXTYMZCGROT-UHFFFAOYSA-N Cc(ccc(O)c1)c1N(CCc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc(ccc(O)c1)c1N(CCc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O HOXCXTYMZCGROT-UHFFFAOYSA-N 0.000 description 2
- YYRPZHKKDKAUNO-UHFFFAOYSA-N Cc(ccc(O)c1)c1[I](C)I Chemical compound Cc(ccc(O)c1)c1[I](C)I YYRPZHKKDKAUNO-UHFFFAOYSA-N 0.000 description 2
- VBZFLMHJMOVMPN-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2-c1ncc(cc(C(C2)CN2C(C=C)=O)cc2)c2c1 Chemical compound Cc(ccc1c2cn[nH]1)c2-c1ncc(cc(C(C2)CN2C(C=C)=O)cc2)c2c1 VBZFLMHJMOVMPN-UHFFFAOYSA-N 0.000 description 2
- ITPAKEQNVKRXGB-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(C=C(C=CC(C(C1)CN1C(C=C)=O)=C1)C1=C1)C1=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(C=C(C=CC(C(C1)CN1C(C=C)=O)=C1)C1=C1)C1=O ITPAKEQNVKRXGB-UHFFFAOYSA-N 0.000 description 2
- ZVZPCVIUVIWKRV-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(C=Cc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(C=Cc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O ZVZPCVIUVIWKRV-UHFFFAOYSA-N 0.000 description 2
- HPUWUPCWYBJVON-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(C=Nc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(C=Nc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O HPUWUPCWYBJVON-UHFFFAOYSA-N 0.000 description 2
- SKSFQHNPOUHWGU-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(CCc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(CCc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O SKSFQHNPOUHWGU-UHFFFAOYSA-N 0.000 description 2
- RDNYSMCXZMOBET-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(CCc1c2ccc(C(CC3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(CCc1c2ccc(C(CC3)CN3C(C=C)=O)c1)C2=O RDNYSMCXZMOBET-UHFFFAOYSA-N 0.000 description 2
- GINIQGONBPQWQR-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2N(Cc(ccc(C(C1)CN1C(C=C)=O)c1)c1N1)C1=O Chemical compound Cc(ccc1c2cn[nH]1)c2N(Cc(ccc(C(C1)CN1C(C=C)=O)c1)c1N1)C1=O GINIQGONBPQWQR-UHFFFAOYSA-N 0.000 description 2
- SXLLCBURWUNMKH-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2Nc1ncnc2c1ccc(C(C1)CN1C(C=C)=O)c2 Chemical compound Cc(ccc1c2cn[nH]1)c2Nc1ncnc2c1ccc(C(C1)CN1C(C=C)=O)c2 SXLLCBURWUNMKH-UHFFFAOYSA-N 0.000 description 2
- KIHDRFDQWVMKES-UHFFFAOYSA-N Cc1c(N)[nH]nc1 Chemical compound Cc1c(N)[nH]nc1 KIHDRFDQWVMKES-UHFFFAOYSA-N 0.000 description 2
- FDQQNNZKEJIHMS-UHFFFAOYSA-N Cc1cc(O)cc(C)c1C Chemical compound Cc1cc(O)cc(C)c1C FDQQNNZKEJIHMS-UHFFFAOYSA-N 0.000 description 2
- WGCXZABXXHHIER-UHFFFAOYSA-N Cc1ccc(cn[nH]2)c2c1C Chemical compound Cc1ccc(cn[nH]2)c2c1C WGCXZABXXHHIER-UHFFFAOYSA-N 0.000 description 2
- PAKCBJMCDXVEFC-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1-c1cc2cc(C(C3)CN3C(C=C)=O)ccc2[nH]1 Chemical compound Cc1ccc2[nH]ncc2c1-c1cc2cc(C(C3)CN3C(C=C)=O)ccc2[nH]1 PAKCBJMCDXVEFC-UHFFFAOYSA-N 0.000 description 2
- DFJWMNHUCMOAQD-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1-c1cc2ccc(C(C3)CN3C(C(c3cccc(c(Nc4ncnc5c4ccc(C(C4)CN4C(C=C)=O)c5)c4)c3cc4O)=C)=O)cc2[nH]1 Chemical compound Cc1ccc2[nH]ncc2c1-c1cc2ccc(C(C3)CN3C(C(c3cccc(c(Nc4ncnc5c4ccc(C(C4)CN4C(C=C)=O)c5)c4)c3cc4O)=C)=O)cc2[nH]1 DFJWMNHUCMOAQD-UHFFFAOYSA-N 0.000 description 2
- VQEYSIDBQNJSEG-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1-c1ncc(cc(C(C2)CN2C(C=C)=O)cc2)c2n1 Chemical compound Cc1ccc2[nH]ncc2c1-c1ncc(cc(C(C2)CN2C(C=C)=O)cc2)c2n1 VQEYSIDBQNJSEG-UHFFFAOYSA-N 0.000 description 2
- KWRVXJNAFVNAIS-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1N(C1)Cc2c1ccc(C(C1)CN1C(C=C)=O)c2 Chemical compound Cc1ccc2[nH]ncc2c1N(C1)Cc2c1ccc(C(C1)CN1C(C=C)=O)c2 KWRVXJNAFVNAIS-UHFFFAOYSA-N 0.000 description 2
- PHKBUIDLVFTMPJ-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1N(CC1)Cc2c1cc(C(C1)CN1C(C=C)=O)cc2 Chemical compound Cc1ccc2[nH]ncc2c1N(CC1)Cc2c1cc(C(C1)CN1C(C=C)=O)cc2 PHKBUIDLVFTMPJ-UHFFFAOYSA-N 0.000 description 2
- IRTOFVHPJCDSPX-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1N(Cc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O Chemical compound Cc1ccc2[nH]ncc2c1N(Cc1c2ccc(C(C3)CN3C(C=C)=O)c1)C2=O IRTOFVHPJCDSPX-UHFFFAOYSA-N 0.000 description 2
- FDRDZDWJVIWTNT-UHFFFAOYSA-N Cc1ccc2c(N)n[nH]c2c1I Chemical compound Cc1ccc2c(N)n[nH]c2c1I FDRDZDWJVIWTNT-UHFFFAOYSA-N 0.000 description 2
- HXICLUNGKDYXRL-UHFFFAOYSA-N Cc1ccc2nn[nH]c2c1C Chemical compound Cc1ccc2nn[nH]c2c1C HXICLUNGKDYXRL-UHFFFAOYSA-N 0.000 description 2
- PPQHHNDXEMBSKB-UHFFFAOYSA-N Cc1cccc(N2)c1NS2(=O)=O Chemical compound Cc1cccc(N2)c1NS2(=O)=O PPQHHNDXEMBSKB-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- JGHPVVNVBIKXKX-UHFFFAOYSA-N C=CC(N(C1)CC1c(cc1)cc(C=CN2c3cc(O)cc4ccccc34)c1C2=O)=O Chemical compound C=CC(N(C1)CC1c(cc1)cc(C=CN2c3cc(O)cc4ccccc34)c1C2=O)=O JGHPVVNVBIKXKX-UHFFFAOYSA-N 0.000 description 1
- JUTVBKHVDGYWBQ-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(CCCN(C2)c3c(cn[nH]4)c4ccc3)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(CCCN(C2)c3c(cn[nH]4)c4ccc3)c2cc1)=O JUTVBKHVDGYWBQ-UHFFFAOYSA-N 0.000 description 1
- PPFCGRQXGAPBDB-UHFFFAOYSA-N C=CC(N(C1)CC1c1cc(CCCN(C2)c3cc(O)cc4ccccc34)c2cc1)=O Chemical compound C=CC(N(C1)CC1c1cc(CCCN(C2)c3cc(O)cc4ccccc34)c2cc1)=O PPFCGRQXGAPBDB-UHFFFAOYSA-N 0.000 description 1
- RYIZKRSVNYQVPV-UHFFFAOYSA-N CC1NC([IH]C)=NC1C Chemical compound CC1NC([IH]C)=NC1C RYIZKRSVNYQVPV-UHFFFAOYSA-N 0.000 description 1
- DJEQZVQFEPKLOY-UHFFFAOYSA-N CCCCN(C)C Chemical compound CCCCN(C)C DJEQZVQFEPKLOY-UHFFFAOYSA-N 0.000 description 1
- NMGNNHBGVMLQJR-UHFFFAOYSA-N COc1cnc(CCCC2)c2c1 Chemical compound COc1cnc(CCCC2)c2c1 NMGNNHBGVMLQJR-UHFFFAOYSA-N 0.000 description 1
- GIHZMBPKJKYQBB-UHFFFAOYSA-N Cc(ccc1c2cn[nH]1)c2-c1nc(cc(C(C2)CN2C(C=C)=O)cc2)c2[nH]1 Chemical compound Cc(ccc1c2cn[nH]1)c2-c1nc(cc(C(C2)CN2C(C=C)=O)cc2)c2[nH]1 GIHZMBPKJKYQBB-UHFFFAOYSA-N 0.000 description 1
- ABUFNULZDMHZTI-UHFFFAOYSA-N Cc1ccc2[nH]ncc2c1N(Cc1c2cc(C(C3)CN3C(C=C)=O)cc1)C2=O Chemical compound Cc1ccc2[nH]ncc2c1N(Cc1c2cc(C(C3)CN3C(C=C)=O)cc1)C2=O ABUFNULZDMHZTI-UHFFFAOYSA-N 0.000 description 1
- GXXCVOZSQBZCCF-UHFFFAOYSA-N Nc1cc(O)cc(I)c1N Chemical compound Nc1cc(O)cc(I)c1N GXXCVOZSQBZCCF-UHFFFAOYSA-N 0.000 description 1
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023008128A JP2023041763A (ja) | 2017-01-26 | 2023-01-23 | 縮合ｎ－複素環式化合物およびその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762450953P | 2017-01-26 | 2017-01-26 | |
| US62/450,953 | 2017-01-26 | ||
| PCT/US2018/015227 WO2018140598A1 (en) | 2017-01-26 | 2018-01-25 | Fused n-heterocyclic compounds and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008128A Division JP2023041763A (ja) | 2017-01-26 | 2023-01-23 | 縮合ｎ－複素環式化合物およびその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505395A JP2020505395A (ja) | 2020-02-20 |
| JP2020505395A5 true JP2020505395A5 (cg-RX-API-DMAC10.html) | 2021-03-04 |
Family
ID=61189554
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019540035A Pending JP2020505395A (ja) | 2017-01-26 | 2018-01-25 | 縮合ｎ−複素環式化合物およびその使用方法 |
| JP2023008128A Pending JP2023041763A (ja) | 2017-01-26 | 2023-01-23 | 縮合ｎ－複素環式化合物およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023008128A Pending JP2023041763A (ja) | 2017-01-26 | 2023-01-23 | 縮合ｎ－複素環式化合物およびその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200385364A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3573966A1 (cg-RX-API-DMAC10.html) |
| JP (2) | JP2020505395A (cg-RX-API-DMAC10.html) |
| CN (1) | CN110382483A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018140598A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (93)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| US10822312B2 (en) | 2016-03-30 | 2020-11-03 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| ES2863873T3 (es) | 2016-05-18 | 2021-10-11 | Mirati Therapeutics Inc | Inhibidores de KRAS G12C |
| CN110366550A (zh) | 2016-12-22 | 2019-10-22 | 美国安进公司 | 作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物 |
| EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
| WO2018140600A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | Fused hetero-hetero bicyclic compounds and methods of use thereof |
| EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
| US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
| WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
| JOP20190272A1 (ar) | 2017-05-22 | 2019-11-21 | Amgen Inc | مثبطات kras g12c وطرق لاستخدامها |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| KR20200010306A (ko) | 2017-05-25 | 2020-01-30 | 아락세스 파마 엘엘씨 | Kras의 공유적 억제제 |
| EP3679040B1 (en) | 2017-09-08 | 2022-08-03 | Amgen Inc. | Inhibitors of kras g12c and methods of using the same |
| US10647715B2 (en) | 2017-11-15 | 2020-05-12 | Mirati Therapeutics, Inc. | KRas G12C inhibitors |
| IL274601B2 (en) | 2017-11-15 | 2024-04-01 | Mirati Therapeutics Inc | Kras g12c inhibitors |
| US11090304B2 (en) | 2018-05-04 | 2021-08-17 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| MA52496A (fr) | 2018-05-04 | 2021-03-10 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| TW202012415A (zh) | 2018-05-08 | 2020-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
| WO2019217691A1 (en) | 2018-05-10 | 2019-11-14 | Amgen Inc. | Kras g12c inhibitors for the treatment of cancer |
| US11096939B2 (en) | 2018-06-01 | 2021-08-24 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| EP3807276B1 (en) | 2018-06-12 | 2025-12-10 | Amgen Inc. | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| US12134620B2 (en) | 2018-08-01 | 2024-11-05 | Araxes Pharma Llc | Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer |
| SG11202102377YA (en) | 2018-09-10 | 2021-04-29 | Mirati Therapeutics Inc | Combination therapies |
| EP3849535A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3111977A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3849536A4 (en) | 2018-09-10 | 2022-06-29 | Mirati Therapeutics, Inc. | Combination therapies |
| EP3628664A1 (en) * | 2018-09-25 | 2020-04-01 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Irreversible inhibitors of kras g12c mutant |
| TWI831855B (zh) | 2018-10-26 | 2024-02-11 | 日商大鵬藥品工業股份有限公司 | 新穎吲唑化合物或其鹽 |
| JP7516029B2 (ja) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法 |
| AU2019384118B2 (en) * | 2018-11-19 | 2025-06-12 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| EP3890716A4 (en) | 2018-12-05 | 2022-12-21 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| JP7592601B2 (ja) | 2019-01-10 | 2024-12-02 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| CN113382774A (zh) | 2019-02-12 | 2021-09-10 | 诺华股份有限公司 | 包含tno155和krasg12c抑制剂的药物组合 |
| CA3131156A1 (en) | 2019-03-05 | 2020-09-10 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| JP7092935B2 (ja) | 2019-05-21 | 2022-06-28 | アムジエン・インコーポレーテツド | 固体形態 |
| PH12022550469A1 (en) | 2019-08-29 | 2023-02-27 | Array Biopharma Inc | Kras g12d inhibitors |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| EP4034123A4 (en) | 2019-09-24 | 2023-11-01 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| CA3158793A1 (en) | 2019-10-28 | 2021-05-06 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12c mutant |
| US11608346B2 (en) | 2019-11-04 | 2023-03-21 | Revolution Medicines, Inc. | Ras inhibitors |
| CR20220240A (es) | 2019-11-04 | 2022-08-03 | Revolution Medicines Inc | Inhibidores de ras |
| IL320513A (en) | 2019-11-04 | 2025-06-01 | Revolution Medicines Inc | RAS inhibitors |
| WO2021092525A1 (en) * | 2019-11-08 | 2021-05-14 | Vanderbilt University | Wdr5 inhibitors and modulators |
| CN114980976A (zh) | 2019-11-27 | 2022-08-30 | 锐新医药公司 | 共价ras抑制剂及其用途 |
| WO2021106230A1 (ja) | 2019-11-29 | 2021-06-03 | 大鵬薬品工業株式会社 | 新規なフェノール化合物又はその塩 |
| WO2021120890A1 (en) | 2019-12-20 | 2021-06-24 | Novartis Ag | Pyrazolyl derivatives useful as anti-cancer agents |
| KR20220130126A (ko) | 2019-12-20 | 2022-09-26 | 미라티 테라퓨틱스, 인크. | Sos1 억제제 |
| CA3181162A1 (en) | 2020-06-05 | 2021-12-09 | Stephen W. Kaldor | Inhibitors of fibroblast growth factor receptor kinases |
| EP4168002A1 (en) | 2020-06-18 | 2023-04-26 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| KR20230137286A (ko) | 2020-09-11 | 2023-10-04 | 미라티 테라퓨틱스, 인크. | Kras g12c 억제제의 결정 형태 |
| US11690915B2 (en) | 2020-09-15 | 2023-07-04 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| MX2023007084A (es) | 2020-12-15 | 2023-08-30 | Mirati Therapeutics Inc | Inhibidores de pan-kras de azaquinazolina. |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022140246A1 (en) | 2020-12-21 | 2022-06-30 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| CR20230558A (es) | 2021-05-05 | 2024-01-24 | Revolution Medicines Inc | Inhibidores de ras para el tratamiento del cáncer |
| CN118561952A (zh) | 2021-05-05 | 2024-08-30 | 锐新医药公司 | Ras抑制剂 |
| US20240293558A1 (en) | 2021-06-16 | 2024-09-05 | Erasca, Inc. | Kras inhibitor conjugates |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| IL309086A (en) | 2021-09-01 | 2024-02-01 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| AU2022365100A1 (en) * | 2021-10-13 | 2024-05-02 | Remix Therapeutics Inc. | Compounds and methods for modulating nucleic acid splicing |
| US20250282782A1 (en) | 2021-12-17 | 2025-09-11 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| WO2023199180A1 (en) | 2022-04-11 | 2023-10-19 | Novartis Ag | Therapeutic uses of a krasg12c inhibitor |
| EP4536364A1 (en) | 2022-06-10 | 2025-04-16 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| AU2023377064A1 (en) | 2022-11-09 | 2025-05-22 | Revolution Medicines, Inc. | Compounds, complexes, and methods for their preparation and of their use |
| CR20250458A (es) | 2023-03-30 | 2025-11-21 | Revolution Medicines Inc | Composiciones para inducir la hidrólisis de ras gtp y sus usos |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024251341A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of a ras inhibitor |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121219016A (zh) | 2023-06-02 | 2025-12-26 | 第一三共株式会社 | 抗-her3抗体-药物缀合物和rasg12c抑制剂的组合 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| US12466840B2 (en) | 2023-10-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Small molecule inhibitors of KRAS proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6143190A (ja) * | 1984-08-06 | 1986-03-01 | Mitsui Petrochem Ind Ltd | ピリドピリミジン誘導体およびその製法 |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
| US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| US5861510A (en) | 1995-04-20 | 1999-01-19 | Pfizer Inc | Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors |
| ATE225343T1 (de) | 1995-12-20 | 2002-10-15 | Hoffmann La Roche | Matrix-metalloprotease inhibitoren |
| BR9710381A (pt) | 1996-07-18 | 1999-08-17 | Pfizer | Inibidores de metaloproteases de matriz - base de fosfinato |
| CN1228083A (zh) | 1996-08-23 | 1999-09-08 | 美国辉瑞有限公司 | 芳基磺酰氨基异羟肟酸衍生物 |
| WO1998030566A1 (en) | 1997-01-06 | 1998-07-16 | Pfizer Inc. | Cyclic sulfone derivatives |
| TR199901849T2 (xx) | 1997-02-03 | 2000-02-21 | Pfizer Products Inc. | Arils�lfonilamino hidroksamik asit t�revleri. |
| CA2279863A1 (en) | 1997-02-07 | 1998-08-13 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
| EA002546B1 (ru) | 1997-02-11 | 2002-06-27 | Пфайзер Инк. | Производные арилсульфонилгидроксамовой кислоты |
| GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
| GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
| PA8469501A1 (es) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico |
| PA8469401A1 (es) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | Derivados biciclicos del acido hidroxamico |
| JP2004250329A (ja) * | 2002-12-26 | 2004-09-09 | Dainippon Pharmaceut Co Ltd | イサチン誘導体 |
| GB0405628D0 (en) * | 2004-03-12 | 2004-04-21 | Glaxo Group Ltd | Novel compounds |
| KR101256018B1 (ko) * | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
| MX355943B (es) * | 2013-06-26 | 2018-05-07 | Abbvie Inc | Carboxamidas primarias como inhibidores de btk. |
| SG11201601138PA (en) * | 2013-08-23 | 2016-03-30 | Neupharma Inc | Certain chemical entities, compositions, and methods |
| JO3805B1 (ar) * | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| KR20170132332A (ko) * | 2015-04-03 | 2017-12-01 | 난트바이오사이언스 인코포레이티드 | 돌연변이 k-ras 표적 방법 및 조성물 |
| CN105348271A (zh) * | 2015-12-23 | 2016-02-24 | 常州润诺生物科技有限公司 | 喹唑啉类衍生物药用用途及其制备方法 |
| CN105399734A (zh) * | 2015-12-23 | 2016-03-16 | 吉林省长源药业有限公司 | 新型egfr抑制剂及其制备方法 |
| CN105924840A (zh) * | 2016-06-01 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种阻燃电力电缆 |
| CN106084164A (zh) * | 2016-06-12 | 2016-11-09 | 四川大学 | 一种结构抗菌型聚氨酯用扩链剂的制备方法 |
-
2018
- 2018-01-25 JP JP2019540035A patent/JP2020505395A/ja active Pending
- 2018-01-25 WO PCT/US2018/015227 patent/WO2018140598A1/en not_active Ceased
- 2018-01-25 CN CN201880008592.8A patent/CN110382483A/zh active Pending
- 2018-01-25 US US16/480,849 patent/US20200385364A1/en not_active Abandoned
- 2018-01-25 EP EP18704371.6A patent/EP3573966A1/en not_active Withdrawn
-
2022
- 2022-06-13 US US17/839,232 patent/US20230147053A1/en not_active Abandoned
-
2023
- 2023-01-23 JP JP2023008128A patent/JP2023041763A/ja active Pending